[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370463-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370463-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ahsa1-hsp90aa1-complex-stabilized-ifi6-and-tgfb1-promotes-mitochondrial-stability-and-emt-in-egfr-mutated-lung-adenocarcinoma-under-osimertinib-pressure","AHSA1-HSP90AA1 complex stabilized IFI6 and TGFB1 promotes mitochondrial stability and EMT in EGFR-mutated lung adenocarcinoma under Osimertinib pressure","","Tyrosine kinase inhibitors improve outcomes for EGFR-mutated lung adenocarcinoma, yet primary resistance limits benefit. AHSA1-HSP90AA1 complex overexpression increases IFI6 levels and markedly enhances Osimertinib resistance by stabilizing mitochondrial function, lowering apoptosis, and supporting survival pathways through increased Akt phosphorylation. TGFB1 further drives epithelial-mesenchymal transition (EMT) and strengthens invasive and migratory abilities, intensifying resistance. Mechanistically, the complex stabilizes IFI6 and TGFB1, promoting cell survival and treatment failure. IFI6 is proposed as a biomarker and therapeutic target against TKI resistance.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ahsa1-hsp90aa1-complex-stabilized-ifi6-and-tgfb1-promotes-mitochondrial-stability-and-emt-in-egfr-mutated-lung-adenocarcinoma-under-osimertinib-pressure/370463/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ahsa1-hsp90aa1-complex-stabilized-ifi6-and-tgfb1-promotes-mitochondrial-stability-and-emt-in-egfr-mutated-lung-adenocarcinoma-under-osimertinib-pressure/370463.png","ImageObject",300,407,{"name":42,"@type":43},"Rhys","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does the AHSA1-HSP90AA1 complex influence Osimertinib resistance?","Question",{"text":63,"@type":64},"It stabilizes IFI6 and TGFB1, enhancing cell survival mechanisms that increase Osimertinib resistance in EGFR-mutated lung adenocarcinoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What role does IFI6 play under Osimertinib pressure?",{"text":68,"@type":64},"IFI6 stabilizes mitochondrial function, reduces apoptosis, and promotes survival pathways via increased Akt phosphorylation, supporting resistance.",{"name":70,"@type":61,"acceptedAnswer":71},"How does TGFB1 affect cancer cell behavior in this study?",{"text":72,"@type":64},"TGFB1 promotes epithelial-mesenchymal transition (EMT) and increases invasive and migratory capabilities, thereby intensifying resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370463,1790252506,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nAHSA1-HSP90AA1 complex stabilized IFI6 and TGFB1 promotes mitochondrial stability and EMT in EGFR-mutated lung adenocarcinoma under Osimertinib pressure  \nYing Sui1,2,3, Ziyang Shen 1,2,3, Rongtian Pan1,2,3, Rong Ma2, Rujia Si2, Jifeng Feng 1,2,3 ✉ and Guoren Zhou1,2,3 ✉  \n© The Author(s) 2025  \n|  |  |  |\n| --- | --- | --- |\n|  | Tyrosine kinase inhibitors (TKIs) have substantially improved the management of lung adenocarcinoma harboring epidermal growth factor receptor (EGFR) mutations, however, not all patients can derive beneﬁt from it. We found that the overexpression of IFI6 under the inﬂuence of the AHSA1-HSP90AA1 complex signiﬁcantly enhances Osimertinib resistance in EGFR-mutated lung adenocarcinoma cells. This effect is achieved by stabilizing mitochondrial function, reducing apoptosis, and promoting cell survival pathways via increased Akt phosphorylation. Additionally, we revealed that TGFB1 further promotes epithelial-mesenchymal transition (EMT) and enhances the invasive and migratory capabilities of these cells, thereby intensifying resistance. Regarding mechanisms, the AHSA1-HSP90AA1 complex stabilizes IFI6 and TGFB1 to enhance cell survival and Osimertinib resistance in EGFR mutant lung adenocarcinoma. IFI6 not only aids in cellular survival under drug stress but also promotes aggressive tumor |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| phenotypes, suggesting its viability as a novel biomarker and therapeutic target for overcoming primary TKI resistance. |  |  |\n|  | Cell Death and Disease (2025)16:298; [https://doi.org/10.1038/s41419-025-07650-9](https://doi.org/10.1038/s41419-025-07650-9) |  |\n|  |  |  |\n\nINTRODUCTION  \nTyrosine kinase inhibitors (TKIs) have signiﬁcantly transformed the management and prognosis of patients with lung adenocarcinoma (LUAD) harboring epidermal growth factor receptor (EGFR) sensitizing mutations [1–3]. Although patients treated with EGFR-TKIs experience extended progression-free survival and high tumor response rates, On-target and off-target resistance pose signiﬁcant obstacles to this therapy[4, 5]. Cell stress factors and their downstream activation play an indispensable role in the resistance to EGFR-TKIs [6, 7]. Whether it is the downstream IL-6 signaling activation caused by LKB1 inhibition under TKI pressure, or TKI resistance induced by secondary hypoxic stress, the impact of these TKI resistance-related molecules and mechanisms on prognosis and predictive value is increasingly being elucidated [8, 9] .  \nAHSA1 (Activator of HSP90AA1 ATPase Activity 1) activates the ATPase activity of HSP90AA1, thereby enhancing its function. HSP90AA1, a cellular stress response protein, is expressed more highly in cancerous tissues than in normal tissues and has been targeted by anticancer therapies for decades [10–14] . Numerous clinical trials involving HSP90AA1 inhibitors have emerged; however, most have not become standard treatments due to the adverse side effects and toxicity that patients ﬁnd difﬁcult to tolerate [15, 16] . This is largely because these inhibitors are too broad-spectrum, suppressing many downstream molecules bound to HSP90AA1 in addition to HSP90AA1 itself [17–19] . Targeting more speciﬁc downstream targets of HSP90AA1 may provide amore viable approach.  \nIn this study, we have revealed that IFI6, an apoptosis-regulating gene, serves as a direct downstream component of the AHSA1/ HSP90AA1 complex. It stabilizes mitochondrial function in EGFR mutant LUAD cells and aids in resistance to Osimertinib stress. This insight promises to provide a new theoretical basis and clinical reference for overcoming primary off-target Osimertinib resistance.  \nRESULTS  \nAHSA1 alleviates the Osimertinib-induced stress in EGFR-mutated lung adenocarcinoma  \nAHSA1 is differentially expressed in the TCGA-LUAD cancer versus adjacent non-cancerous samples, and higher expressio","cbCait8QjImAsylq","https://ap.wps.com/l/cbCait8QjImAsylq","pdf",11581054,14,"English","# Introduction\n# Results\n## AHSA1 alleviates the Osimertinib-induced stress in EGFR-mutated lung adenocarcinoma","[{\"question\":\"How does the AHSA1-HSP90AA1 complex influence Osimertinib resistance?\",\"answer\":\"It stabilizes IFI6 and TGFB1, enhancing cell survival mechanisms that increase Osimertinib resistance in EGFR-mutated lung adenocarcinoma.\"},{\"question\":\"What role does IFI6 play under Osimertinib pressure?\",\"answer\":\"IFI6 stabilizes mitochondrial function, reduces apoptosis, and promotes survival pathways via increased Akt phosphorylation, supporting resistance.\"},{\"question\":\"How does TGFB1 affect cancer cell behavior in this study?\",\"answer\":\"TGFB1 promotes epithelial-mesenchymal transition (EMT) and increases invasive and migratory capabilities, thereby intensifying resistance.\"}]","AHSA1-HSP90AA1 complex stabilized IFI6 and TGFB1 promotes mitochondrial stability and EMT in EGFR-mutated lung adenocarcinoma under Osimertinib pressure | PDF",1790188672,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/02daa5feb712c55a4986836f2909f72a.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/802828bd08377c316af2c2ba72cef792.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/feea66b5240615094d3be051b768743d.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06a904cbbfaa937cfae6dd4e26505b09.webp",980,1301]